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ABSTRACT
In a previous study comparing fluconazole and itraconazole administered as antifungal prophylaxis in hema-
topoietic cell transplant (HCT) recipients, we found that fluconazole administration concurrent with cyclo-
phosphamide (CY)-based conditioning was associated with fewer early toxicities compared to itraconazole.
Fluconazole inhibits cytochrome P450 2C9, which is involved with the activation of CY, and so might provide
protection from CY-related toxicities. To investigate this further, we compared CY and CY-metabolite data
from patients who received fluconazole (n  56) concurrent with CY-containing conditioning and in patients
who did not (n  17). The fluconazole group had greater exposure to CY, and lower peak serum concentration
of CY-metabolite 4-hydroxycyclophosphamide. In a separate cohort, we examined outcomes in patients
randomized to receive either fluconazole (n  152) or placebo (n  147) concurrent with CY-containing
conditioning in a prior randomized trial. Patients who received fluconazole experienced less hepatic and renal
toxicity, and had lower mortality. No difference in relapsed malignancy was apparent. These data support the
hypothesis that fluconazole, when coadministered with CY, decreases CY-related toxicities by inhibiting
cytochrome P450 2C9 metabolism.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Cyclophosphamide (CY) is an alkylating agent
sed commonly in myeloablative conditioning regi-
ens for hematopoietic cell transplantation (HCT)
1]. It is a pro-drug that undergoes 3 metabolic
athways: (1) urinary elimination as unchanged CY;
2) detoxiﬁcation via cytochrome P450 (CYP) 3A4/5
o dechloroethyl-cyclophosphamide (DCCY); and
3) activation via CYP 2A6, 2B6, 3A4, 3A5, 2C9,
C18, and 2C19 to 4-hydroxycyclophosphamide
HCY). HCY is then converted by -elimination to
oxins acrolein, which is primarily responsible for
rothelial toxicity, and phosphoramide mustard (PM),
esponsible for antineoplastic activity. Other metabo- a
60ites include o-carboxyethyl-phosphoramide mustard
CePM), 4-keto-cyclophosphamide (ketoCY), and hy-
roxypropyl-phosphoramide mustard (HPPM).
We have previously published early toxicity data
rom a randomized trial comparing ﬂuconazole with
traconazole as antifungal prophylaxis in HCT recip-
ents; results demonstrated a disequilibrium in CY-
etabolites, and renal and hepatic toxicities in pa-
ients who received the azole drugs concurrent with
Y-containing regimens [2,3]. Coadministration of
igh-dose ﬂuconazole (400 mg daily) with CY was
ssociated with greater exposure to CY and DCCY,
hereas itraconazole (2.5 mg/kg 3 times daily) was
ssociated with greater exposure to HCY, ketoCY,
nd (to a lesser extent) CePM [3]. In addition, con-
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Fluconazole and Cyclophosphamide Metabolism 761urrent ﬂuconazole was associated with less renal and
epatic toxicity, and a trend to improved survival at
ay 20. We hypothesized that, through its inhibition
f CYP2C9 metabolism of CY to HCY, high-dose
400 mg daily) ﬂuconazole coadministration may re-
ult in less exposure to HCY metabolites, including
oxins responsible for tissue injury. As this implies a
otential protective effect of ﬂuconazole administered
uring CY-containing conditioning, we have investi-
ated this interaction further. Speciﬁcally, we exam-
ned CY and CY-metabolite data from 2 cohorts of
CT recipients. One cohort received ﬂuconazole
oncurrent with CY-based conditioning and another
id not. We also reexamined toxicity data from a study
f HCT recipients randomized to receive either ﬂu-
onazole or placebo as antifungal prophylaxis.
ATERIALS AND METHODS
tudy 1. Pharmacokinetics of CY
CY-metabolite data were available from a cohort
f 73 allogeneic HCT recipients treated with busulfan
BU)-CY conditioning and variable antifungals, from
001 to 2005, inclusive. HCTs were performed ac-
ording to standard institutional practices. Seven days
efore the infusion of stem cells, CY was infused
hrough a central venous catheter over 1 to 2 hours at
dose of 60 mg/kg body weight. On the following
ay, a second infusion of CY was given, at the same
ose. All patients were given antiseizure prophylaxis
ith phenytoin. Phenytoin loading dose (10-15 mg/
g) was completed at least 6 hours before the ﬁrst dose
f BU. Institutional standard practice was to admin-
ster ﬂuconazole concomitant with (on or before) con-
itioning. A subset of patients received alternative
egimens because of physician decision or randomiza-
ion into a trial that began prophylaxis (ﬂuconazole or
oriconazole) after conditioning (with receipt of stem
ells).
Blood samples were removed from a non-CY in-
usion port of a central venous access catheter, and
laced into tubes containing either p-nitrophenyl hy-
razine for analysis of HCY or EDTA (ethylenedia-
inetetraacetic acid) for other analytes. They were
hen mixed and centrifuged at the bedside. Plasma was
mmediately removed, frozen and stored at 80°C
ntil analysis. CY and CY-metabolites (HCY and
ePM) were measured mid-infusion, at the end of the
nfusion, and at 1, 3, 7, 20, and 24 hours after infusion.
xposure to CY and CY-metabolites was expressed as
he area under the curve (AUC; mM/h) derived from
he time of the ﬁrst CY dose to 24 hours after the
econd CY dose [4]. In addition, the peak concentra-
ion (Cmax, M) of CY and HCY were measured after
he ﬁrst and second CY doses. Baseline (day before
u-CY conditioning) and daily (until HCT day 20) ﬂerum creatinine and total bilirubin levels were re-
orded.
tudy 2. Antifungal Prophylaxis Study
To evaluate the hypothesis that ﬂuconazole de-
reases the frequency of toxicities because of CY-
ontaining conditioning, clinical outcomes (hepatic
nd renal toxicities, and survival) were compared in
99 patients who received ﬂuconazole (400 mg daily,
rally or intravenously) or placebo concurrent with
Y (beginning on the day of CY-containing condi-
ioning), as part of a previously published antifungal
rophylaxis trial [5]. This study enrolled primarily
llogeneic HCT recipients (88%) between 1990 and
992. HCTs were performed according to standard
ractice. Conditioning regimens included CY-total
ody irradiation (TBI) (placebo, n  82; ﬂuconazole,
 97), BU-CY (placebo, n  51; ﬂuconazole, n 
9), BU-CY-TBI (placebo, n  14; ﬂuconazole, n 
6), P .23. All patients receiving BU (n 120) were
iven antiseizure prophylaxis with phenytoin. Phenyt-
in loading dose (10-15 mg/kg) was completed at least
hours before the ﬁrst dose of BU. Renal and hepatic
oxicities, survival, and the probability of mortality not
elated to fungal infection were compared. Renal tox-
city was deﬁned as doubling of baseline creatinine
oncentration (mg/dL) and hepatic toxicity was eval-
ated as daily total serum bilirubin level (mg/dL).
Both studies were approved by the Fred Hutchin-
on Cancer Research Center institutional review
oard. All patients provided informed consent.
tatistical Considerations
Continuously valued outcomes were compared us-
ng a Wilcoxon rank sum test. Survival estimates at
ays 20 and 75 were calculated using Kaplan-Meier
ethodology. Nonfungal mortality was calculated us-
ng cumulative incidence estimates. Time from trans-
lant to death without prior fungal infection was the
ndpoint of interest and fungal infections were treated
s competing risk events. Both survival and nonfungal
ortality were compared using a log-rank test to day
0 and day 75. All P-values are 2-sided.
ESULTS
tudy 1
In study 1, we compared AUC-CY, AUC-HCY,
nd AUC-CEPM in patients receiving ﬂuconazole
400 mg daily) concurrent with CY-containing condi-
ioning (group 1, n  56) with those patients who did
ot (group 2, n  17). In group 2, antifungal prophy-
axis included lipid amphotericin at conditioning (n 
), caspofungin at conditioning (n  1), ﬂuconazole at
ay 0 (n  1), itraconazole at day 1 (n  1), and
uconazole or voriconazole (patients enrolled in a ran-
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A. Upton et al.762omized blinded study) at day 0 ofHSCT (n 12). Data
omparing the AUC for CY, CePM andHCY, and Cmax
or CY and HCY are shown in Table 1. The ﬂuconazole
reated patients (group 1) had greater AUC-CY (P 
0001). Although there was no signiﬁcant difference in
UC-HCY between the 2 groups, ﬂuconazole recipients
ad a lower median Cmax-HCY after doses 1 and 2 (P
0002 and P  .006, respectively). Data comparing se-
um creatinine and total bilirubin for the ﬁrst 20 days
ollowing HCT are shown in Table 2. No signiﬁcant
ifference in maximum creatinine level or number of
atients reaching 2 baseline was observed. There
ere nonsigniﬁcant trends to higher maximum and daily
otal serum bilirubin levels in the ﬂuconazole group
group 2).
tudy 2
The analysis above likely did not include enough
atients to observe signiﬁcant differences in clinical
utcomes. We postulated that differences in clinical
utcomes may be more reliably measured in patients
nrolled in our prior ﬂuconazole versus placebo trial,
hich randomized 152 patients to receive ﬂuconazole
nd 148 patients to receive placebo, with both drugs
nitiated with conditioning therapy [5]. The probability
f survival was greater at days 20 and 75 following HCT
n patients receiving ﬂuconazole, 95% versus 89%, P 
04 and 83% versus 74%, P  .06, respectively (Figure
A). There was a trend to lower nonfungal mortality at
able 1. Area Under the Curve (AUC) and Peak Serum Concentratio
onditioning for Hematopoietic Cell Transplant (HCT)—Study 1
Drug/metabolite—median (range) Group 1, n
UC-CY 2628 (1375
UC-CePM 489 (215-
UC-HCY 272 (92-7
max-CY following dose 1 305 (92-7
max-CY following dose 2 282 (153-
max-HCY following dose 1 29 (10-5
max-HCY following dose 2 31 (10-6
ote: Group 1 consists of patients receiving ﬂuconazole concurren
nonazole antifungal agent with CY.
UC indicates area under the curve; CY, cyclophosphamide; CePM
mide; Cmax, peak serum concentration.
able 2. Creatinine and Bilirubin Levels from Patients Recieving CY-C
Y-Containing Conditioning) and Daily for the ﬁrst 20 Days Post-HSC
Factor
reatinine (mg/dL)
aximum difference from baseline—median (range)
Number reaching >2 baseline (%)
ilirubin (mg/dL)
Maximum level—median (range)
Daily level—median (range)
ote: Group 1 consists of patients receiving ﬂuconazole concurren
nonazole antifungal agent with CY.ays 20 and 75 in recipients of ﬂuconazole (Figure 1B).
here was no difference in the probability of relapse of
nderlying malignancy at day 110 between patients re-
eiving ﬂuconazole or placebo (p .42) [5]. Differences
n early toxicities were observed in ﬂuconazole recipients
Table 3). Speciﬁcally, fewer ﬂuconazole recipients,
ompared with placebo, experienced a doubling of base-
ine creatinine (34% versus. 47%, P  .02) during the
rst 20 days following HCT. The median daily total
erum bilirubin level was also lower in the patients re-
eiving ﬂuconazole [2.0 (range 0.4-27.7) versus 2.5
range 0.3-27.8), P  .05].
ISCUSSION
Cyclophosphamide pharmacokinetics data pre-
ented here support the hypothesis that high dose
uconazole (400 mg daily), when coadministered with
Y-containing conditioning, has an inhibitory effect
n CY activation, resulting in greater CY exposure,
hich may result in fewer conditioning-related toxic-
ties. Toxicity and survival data from 2 prospective
andomized studies (study 2 presented here, and a
reviously published study [3]) indicate an advantage
mong patients receiving ﬂuconazole concurrent with
Y-containing conditioning, compared with placebo
this study) or itraconazole [3].
Our ﬁnding that recipients of ﬂuconazole concur-
ent with CY had higher AUC-CY is consistent with
) of CY and HCY following First and Second Doses of CY-Containing
Group 2, n  17 P
1465 (933-3431) <.0001
500 (271-738) .686
297 (194-353) .4395
223 (145-302) <.0001
212 (19-403) .0001
43 (25-68) .0002
43 (20-60) .0056
CY, and group 2 consists of patients receiving either no drug or a
oxyethyl-phosphoramide mustard; HCY, 4-hydroxycyclophospha-
ing Conditioning for HCT, Measured at Baseline (Immediately before
dy 1
up 1, n  56 Group 2, n  17 P
(0-2.90) 0.20 (0.00-2.10) .62
(16%) 3 (18%) .28
(0.70-12.20) 1.90 (0.90-33.50) .28
(0.47-5.17) 1.18 (0.59-11.57) .18
CY, and group 2 consists of patients receiving either no drug or an (Cmax
 56
-8086)
1165)
44)
44)
1064)
3)
5)
t with
, o-carbontain
T—Stu
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9
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Fluconazole and Cyclophosphamide Metabolism 763he results of a small case-controlled study that com-
ared plasma clearance of CY in children receiving
uconazole and CY concurrently (cases, n  9) with
hildren receiving CY alone (controls, n  13). In this
tudy, cases had signiﬁcantly lower plasma clearance
f CY and higher AUC-CY [6].
In our study, patients who received ﬂuconazole
oncurrently with CY had greater AUC-CY and
max-CY, and lower Cmax-HCY, with equivalent
UC-HCY. These data suggest that inhibition of CY
ctivation leads to a reduced rate of HCY formation.
he comparable AUC-HCY and lower Cmax-HCY
uggests prolongation of HCY elimination. Similar
igure 1. A, Probability of overall survival and B, nonfungal mortality
fter HSCT—Study 2. Probability of overall survival and nonfungal
ortality in patients receiving ﬂuconazole with CY-conditioning and
n patients receiving placebo with CY-conditioning.
able 3. Creatinine and Bilirubin Levels from Patients Receiving Fluco
or HCT—Study 2
Factor
reatinine (mg/dL)
Maximum difference from baseline—median (range)
Number reaching >2 baseline (%)
ilirubin (mg/dL)
Maximum level—median (range)
Daily level—median (range)
ote: Creatinine and bilirubin levels were measured at baseline (imm
post-HCT.ndings have been reported from a recent study com-
aring CY metabolism in wild-type and hepatic cyto-
hrome P450 reductase knockout mice. Although the
nockout mice had reduced CY elimination (thus,
reater AUC-CY) and reduced Cmax-HCY, no differ-
nce in AUC-HCY between the 2 groups was seen, as
he elimination of HCY was prolonged [7]. Interest-
ngly, in the mouse model, myelotoxicity correlated
ore closely with Cmax-HCY than with AUC-HCY
7]. In contrast, much of the published literature re-
orts an association between exposure to CY-metab-
lites and hepatic toxicity among patients treated with
arious CY-containing chemotherapy regimens. de
onge et al. [8] found that ﬁrst-course AUC-HCY, but
ot AUC-PM, predicted the occurrence of veno-oc-
lusive disease (VOD) after multiple courses, while
uitema et al. [9] reported a trend to an association
etween AUC-HCY and VOD. McDonald et al. [4]
ound no association between AUC-HCY and VOD,
ut an association between AUC-CePM and VOD,
levated bilirubin, and nonrelapse mortality was ob-
erved. They hypothesize that the chemically stable
ePM reports on intrahepatic exposure to acrolein
nd PM formed from HCY.
Among study 1 patients, we did not observe a
ifference in hepatic and renal toxicity during the ﬁrst
0 days following HCT between those patients who
eceived ﬂuconazole with CY-based conditioning and
hose who did not. If Cmax-HCY correlates best with
oxicity we would expect to see a signiﬁcant difference;
ur data demonstrating no difference in AUC-HCY
nd toxicities argues in favor of the hypothesis that
UC-HCY correlates with (at least hepatic and renal)
oxicities following CY administration. It is also pos-
ible that there were not enough patients examined to
bserve meaningful clinical differences. These toxicity
ata should be interpreted with caution, as patients
ompared in the 2 groups were matched only in that
hey received myeloablative doses of CY and Bu, and
eceived phenytoin.
In contrast, differences in clinical outcomes were
easured in patients that received ﬂuconazole or pla-
ebo concomitant with CY in our prior randomized
rial. As azole antifungal agents are associated with
Prophylaxis or Placebo Concurrent with CY-Containing Conditioning
ebo, n  147 Fluconazole, n  152 P
(0.10-5.00) 0.40 (0.00-4.60) .04
(47%) 51 (34%) .02
(0.50-56.9) 3.65 (0.50-64.50) .09
(0.30-27.84) 2.03 (0.40-27.71) .05
ly before CY-containing conditioning) and daily for the ﬁrst 20 daysnazole
Plac
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A. Upton et al.764epatotoxicity (particularly transaminitis) these ﬁnd-
ngs are the converse of what might be expected,
trengthening our hypothesis of an interaction be-
ween ﬂuconazole and CY activation.
When interpreting our data, one must be mindful
f the additional role that phenytoin may play in CY
etabolism. As phenytoin is an inducer of CYP450
nzymes, coadministration with CY may exert the
pposite effect of ﬂuconazole, by inducing CY activa-
ion resulting in greater HCY (and other metabolite)
xposure. However, in study 1 all patients received
henytoin, whereas in study 2 approximately 1/3 of
atients did not. As the 2 groups compared in study 2
ere matched for phenytoin exposure, we do not be-
ieve that this should introduce signiﬁcant bias.
In summary, we have demonstrated that at high
oses (400 mg daily) ﬂuconazole may have an impact
n CY activation, exerting a protective effect against
Y-related toxicities. However, these drug/metabolite
ata are limited by the retrospective nature of the
tudy; we cannot conclude that the differences seen
re deﬁnitely from a ﬂuconazole-CY interaction. A
andomized trial speciﬁcally addressing early toxicities
s well as therapeutic effects, with concurrent mea-
urements of CY and CY-metabolites, needs to be
one to deﬁnitively answer this question.
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